全球 NAMPT 抑製剂市场——按分子类型、治疗领域、适应症、给药途径、治疗线和主要区域分析：行业趋势和未来预测 (2022-2040)

本报告分析了全球 NAMPT 抑製剂市场，概述了产品、当前临床试验和市场趋势、相关专利申请和批准的趋势、主要投资、资金和补贴的趋势，我们正在调查业务趋势联盟与合作，分领域和区域（2022-2040）的市场趋势预测，主要公司的概况和产品组合，以及业内人士的观点。

内容

第 1 章执行摘要

第二章介绍

• NAMPT 抑製剂概述
• 与 NAMPT 抑製剂相关的重大历史事件
• NAMPT 抑製剂：近期活动
• NAMPT 抑製剂：作用机制
• NAMPT 抑製剂：主要目标适应症

第三章市场状况

• NAMPT 抑製剂：管道产品分析
• NAMPT 抑製剂：开发公司的现状

第四章商业联盟与合作

• NAMPT 抑製剂：商业联盟与合作

第五章融资与投资

• NAMPT 抑製剂：资金和投资

第六章：资助分析

• 分析范围和方法
• NAMPT 抑製剂：NIH（美国国立卫生研究院）提供的资助清单

第七章企业竞争力

• 主要假设和指标
• 分析方法
• 投资组合强度基准
• 合作活动基准
• 基准筹款活动
• 投资组合强度基准
• NAMPT 抑製剂：公司竞争力分析

第八章公司简介

• 德琪医药
• 水肺疗法
• 核药疗法
• Onco Tartis
• 昂西奥

第9章出版物分析

• 分析方法和关键指标
• NAMPT 抑製剂：出版物列表

第10章国际事件分析

• 分析方法和关键指标
• NAMPT 抑製剂：国际事件列表

第 11 章社交媒体分析

• 分析方法和关键指标

第12章药物失效分析

• 分析方法和关键指标
• NAMPT 抑製剂：失败的候选药物列表

第 13 章 FDA 批准策略

• 分析方法和关键指标
• NAMPT 抑製剂试验失败的常见原因和开发人员采用的关键策略
• 每家公司采用□□的特定于製药业的商业模式
• 候选药物分析：按商业模式

第十四章市场预测与机会分析

• 分析方法和关键指标
• 预测方法
• 全球 NAMPT 抑製剂市场 (2027-2040)
• 预测药物清单
• NAMPT 抑製剂市场：按分子类型分析 (2027/2040)
• NAMPT 抑製剂市场：按治疗领域分析（2027 年和 2040 年）
• NAMPT 抑製剂市场：按目标适应症分析 (2027/2040)
• NAMPT 抑製剂市场：按治疗线分析 (2027/2040)
• NAMPT 抑製剂市场：按给药途径分析 (2027/2040)
• NAMPT 抑製剂：主要公司的市场份额
• NAMPT 抑製剂市场：区域分析 (2030-2040)

第十五章企业高管的思考

第 16 章附录 1：图表列表

第17章附录2：公司和组织名单

INTRODUCTION

Globally, cancer is one of the leading causes of death; in 2020, about 10 million cancer related deaths were reported. Further, according to a study published in American Cancer Society Journal, by 2040, the number of cancer cases is projected to reach over 28 million, indicating a cumulative growth of nearly 47%, since 2020. The continuous growth in the number of cancer patients imposes a huge burden, in terms of finances as well as resources, on the overall healthcare system. In this context, it is worth mentioning that the annual expenditure associated with cancer care is more than USD 200 billion, in the US alone. Given the fact that majority of the current treatment options for cancer have proven to be inadequate, especially for late-stage cancers, there is a high demand for highly effective therapeutics. Over time, many research studies have demonstrated that NAMPT (Nicotinamide Phosphoribosyl Transferase) can interfere with the metabolism of NAD+, which is known to be the fuel for tumor cells; this notion has encouraged several researchers to conduct extensive studies for the development of novel and efficacious drug candidates, such as NAMPT inhibitors.

NAMPT inhibitors are being evaluated to target a wide range of indications, primarily focusing on oncological disorders. Given the encouraging research outcomes, the domain has attracted the attention of many private and public investors who have made investments worth more than USD 650 million, since 2018. Driven by the increasing R&D activity, promising clinical data and financial support from investors, the NAMPT inhibitors market is anticipated to grow at a commendable pace in the mid to long-term.

SCOPE OF THE REPORT

The "NAMPT Inhibitors Market, Distribution by Type of Molecule (Small Molecules and Biologics), Therapeutic Area (Oncological and Respiratory Disorders), Indication (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia), Route of Administration (Oral and Intravenous), Line of Treatment (1st Line and 2nd Line), and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of NAMPT inhibitors in the healthcare domain, till 2040. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space. Amongst other elements, the report includes:

• A brief introduction to important concepts related to NAMPT inhibitors, featuring information on key historical events, key indications targeted by such therapeutics, potential concerns associated with their use and mechanism of action. This chapter further features details related to the recent advancements that have been made in the NAMPT inhibitors market.

• A detailed overview of the current market landscape of NAMPT targeting drug candidates that are currently being researched in pre-clinical and clinical studies, featuring an elaborate analysis of such therapies based on several relevant parameters, such as phase of development (preclinical, phase I, phase I/II and phase II), type of molecule (small molecules and biologics), route of administration (oral and intravenous), target indication (acute myeloid leukemia, acute respiratory distress syndrome, hodgkin lymphoma, and non-hodgkin lymphoma), line of treatment (1st line and 2nd line) and type of therapy (monotherapy and combination therapy).

• An elaborate analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in the domain of NAMPT inhibitors since 2022, including a brief description of the various partnership models adopted (including product development and commercialization agreement, product development, manufacturing and commercialization agreement, mergers and research and development agreement).

• An insightful analysis of recent funding instances that have been reported by several players engaged in the NAMPT inhibitors domain, including details on the year of funding, amount received and type of funding (awards / grants, venture series, initial public offering, secondary offerings, debt financing and other equity).

• An in-depth analysis on various grants, since the year 2022, received by players engaged in this field based on year of award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers.

• An insightful company competitiveness analysis of NAMPT inhibitor targeting therapy developers, based on several relevant parameters, such as the firm's portfolio strength (taking into consideration number of drugs in pipeline, phase of development and type of molecule), partnership strength (in terms of the number of partnerships established and partnership year) and funding strength (in terms of number of funding instances, amount of funding, year of funding, type of funding and number of lead investors).

• Elaborate profiles of prominent players that are engaged in the development of NAMPT inhibitors, featuring a brief overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments and an informed future outlook.

• A detailed analysis of several peer-reviewed, scientific articles related to research on NAMPT inhibitors, over last 12 years, based on several relevant parameters, such as year of publication, type of publication and popular keywords.

• An analysis of the global events attended by industry players, based on several relevant parameters, such as year of event, event platform, type of event, leading presenters (in terms of number of participations) and leading players (in terms of number of participations).

• An analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter, based on several relevant parameters, such as year of tweet, top users and emerging focus areas.

• An in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development, based on various relevant parameters, such as phase of discontinuation, target indication, route of administration and type of molecule.

• A proprietary analysis on various competitive strategies that can be implemented by drug developers engaged in this domain, to expedite the FDA approval process for their proprietary products; it includes information on several relevant parameters, such as clinical evidence, awards / grants, research findings, partnerships, other financial support received and others.

• A detailed market forecast analysis, highlighting the likely growth of the NAMPT inhibitors in the healthcare market, over the period 2022-2040, based on several relevant parameters, such as target patient population, likely launch year of therapy candidates, approval timeline of drugs, likely price points and expected rates of adoption, across various geographical regions. The report also features the likely distribution of the current and forecasted opportunity related to NAMPT inhibitors market across type of molecule (small molecules and biologics), therapeutic area (oncological and respiratory disorders), indication (non-hodgkin lymphoma, hodgkin lymphoma, acute respiratory distress syndrome, and acute myeloid leukemia), route of administration (oral and intravenous), line of treatment (1st line and 2nd line), and key geographical regions (North America, Europe, Asia and Rest of the World).

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

• Annual reports
• Investor presentations
• SEC filings
• Industry databases
• News releases from company websites
• Government policy documents
• Industry analysts' views

While the focus has been on forecasting the market over the coming decade, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

• Who are the leading players engaged in the development of NAMPT inhibitors?

• What types of partnership models are commonly adopted by industry stakeholders engaged in this industry?

• Who are the key investors in the NAMPT inhibitors domain?

• What is the evolving trend of publications focused on NAMPT inhibitors?

• What are the prominent reasons for failure of such therapeutics in their respective clinical / preclinical studies?

• What are the strategic initiatives undertaken by players engaged in this market space related to research and development of NAMPT inhibitors?

• What are the key value drivers that are likely to influence the evolution of this upcoming market?

• How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 1 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of NAMPT inhibitors market and its likely evolution in the short to mid and long term.

Chapter 2 is an introductory chapter that highlights important concepts related to NAMPT inhibitors. It also features information on key historical events, key indications targeted by such therapeutics, potential concerns associated with their use and mechanism of action. This chapter further features details related to recent advancements that have been made in the NAMPT inhibitors market.

Chapter 3 provides information on NAMPT targeting drug candidates that are currently being researched in pre-clinical and clinical studies. The chapter features an elaborate analysis of such therapies based on several relevant parameters, such as phase of development (preclinical, phase I, phase I/II and phase II), type of molecule (small molecules and biologics), route of administration (oral and intravenous), target indications (acute myeloid leukemia, acute respiratory distress syndrome, hodgkin lymphoma, and non-hodgkin lymphoma), line of treatment (1st line and 2nd line), type of therapy (monotherapy and combination therapy). In addition, it provides details on the companies engaged in the development of such compounds, along with information on their year of establishment, company size, and geographical location.

Chapter 4 features an analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in the domain of NAMPT inhibitors since 2022. The chapter includes a brief description of the various partnership models adopted (including product development and commercialization agreement, product development, manufacturing and commercialization agreement, mergers and research and development agreement). Additionally, it comprises of analysis based on the year of partnership and type of partnership. Further, it consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents

Chapter 5 presents an insightful analysis of recent funding instances that have been reported by several players engaged in the NAMPT inhibitors domain. The chapter comprises of analysis based on the year of funding, amount received and type of funding (awards / grants, venture series, initial public offering, secondary offerings, debt financing and other equity). Further, it consists of a schematic representation showcasing the key investors (in terms of number and amount of investment); in addition, it also showcases key players (in terms of number and amount of funding received). Furthermore, we have provided a world map representation of the funding instances received in this field, highlighting those that have been established within and across different continents

Chapter 6 features an in-depth analysis on various grants, since the year 2022, received by players engaged in this field based on year of award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers

Chapter 7 provides an insightful company competitiveness analysis of NAMPT inhibitor targeting therapy developers, based on several relevant parameters, such as the firm's portfolio strength (taking into consideration number of drugs in pipeline, phase of development and type of molecule), partnership strength (in terms of the number of partnerships established and partnership year) and funding strength (in terms of number of funding instances, amount of funding, year of funding, type of funding and number of lead investors). After calculating the final score, companies considered in our analysis were plotted on a 3×3 matrix, with company experience and company competitiveness (calculated using portfolio strength, partnership strength and funding strength) on the x-axis and y-axis respectively. Company size was further represented by the bubble size.

Chapter 8 features elaborate profiles of prominent players that are engaged in the development of NAMPT inhibitors, featuring a brief overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments and an informed future outlook

Chapter 9 consists of a detailed analysis of nearly 70 peer-reviewed, scientific articles related to research on NAMPT inhibitors, over last 12 years, based on several relevant parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on the most popular publishers, most popular journals, and a schematic geographical representation of affiliated organizations

Chapter 10 features an analysis of the global events attended by industry players, based on several relevant parameters, such as year of event, event platform, type of event, leading presenters (in terms of number of participations) and leading players (in terms of number of participations). The chapter also features geographical distribution of events focused on NAMPT inhibitors

Chapter 11 features an analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter, based on several relevant parameters, such as year of tweet, top users and emerging focus areas

Chapter 12 includes an in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development; based on various relevant parameters, such as phase of discontinuation, target indication, route of administration and type of molecule. This chapter explicitly highlights the prominent reasons for drug failure with detailed information on associated instances of such drugs

Chapter 13 features a proprietary analysis on various competitive strategies that can be implemented by drug developers engaged in this domain, to expedite the FDA approval process for their proprietary products; it includes information on several relevant parameters, such as clinical evidence, awards/grants, research findings, partnerships, other financial support received and others. This chapter includes detailed strategies adopted by key developers to ameliorate their proprietary pipeline candidates. In addition, the drugs have been benchmarked using various relevant parameters using interesting representations such as wind-rose and spider web chart

Chapter 14 includes an informed estimate of the likely evolution of the overall NAMPT Inhibitors Market over the period 2022-2040, including the likely distribution of the current and future opportunity across a variety of market segments such as, type of molecule (small molecules and biologics), therapeutic area (oncological and respiratory disorders), indication (non-hodgkin lymphoma, hodgkin lymphoma, acute respiratory distress syndrome, and acute myeloid leukemia), route of administration (oral and intravenous), line of treatment (1st line and 2nd line), and key geographical regions (North America, Europe, Asia and Rest of The World)

Chapter 15 includes interview transcript of discussion held with key stakeholder engaged in this space. The chapter provides a brief overview of the company and details of the interview

Chapter 16 is an appendix, which contains the list of figures and list of tables presented in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 INTRODUCTION

• 2.1. Overview of NAMPT Inhibitors
• 2.2. Key Historical Events Related to NAMPT Inhibitors
• 2.3. NAMPT Inhibitors: Recent Activity
• 2.4. NAMPT Inhibitors: Mechanism of Action
• 2.5. NAMPT Inhibitors: Key Target Indications

3 MARKET LANDSCAPE

• 3.1. NAMPT Inhibitors: Pipeline Review
  • 3.1.1. Analysis by Phase of Development
  • 3.1.2. Analysis by Type of Molecule
  • 3.1.3. Analysis by Phase of Development and Type of Molecule
  • 3.1.4. Analysis by Type of Therapy
  • 3.1.5. Analysis by Line of Treatment
  • 3.1.5. Analysis by Route of Administration
• 3.2. NAMPT Inhibitors: Developer Landscape
  • 3.2.1. Analysis by Type of Player
  • 3.2.2. Analysis by Year of Establishment
  • 3.2.3. Analysis by Location of Headquarters
  • 3.2.4. Analysis by Location of Headquarters and Stage of Development
  • 3.2.5. Analysis by Location of Headquarters and Phase of Development
  • 3.2.6. Analysis by Location of Headquarters and Type of Molecule

4 PARTNERSHIPS AND COLLABORATIONS

• 4.1. NAMPT Inhibitors: Partnerships and Collaborations
  • 4.1.1. Analysis by Year of Partnership
  • 4.1.2. Analysis by Type of Partnership
  • 4.1.3. Analysis by Year and Type of Partnership
  • 4.1.4. Analysis by Type of Agreement
  • 4.1.5. Analysis by Intercontinental and Intracontinental Deals
  • 4.1.6. Active Players: Analysis by Number of Partnerships

5 FUNDING AND INVESTMENTS

• 5.1. NAMPT Inhibitors: Funding and Investments
  • 5.1.1. Analysis of Instances by Year
  • 5.1.2. Analysis of Amount Raised by Year
  • 5.1.3. Analysis of Number of Instances Year and Type of Funding
  • 5.1.4. Analysis of Amount Raised by Year and Type of Funding
  • 5.1.5. Analysis of Number of Instances by Type of Funding
  • 5.1.6. Analysis of Amount Raised by Type of Funding
  • 5.1.7. Most Active Investors: Analysis by Number of Funding Instances
  • 5.1.8. Active Players: Analysis by Number of Instances
  • 5.1.9. Active Players: Analysis by Amount Raised
  • 5.1.10. Analysis of Instances by Geography
  • 5.1.11. Analysis of Total Amount Raised by Geography
  • 5.1.12. Analysis of Total Amount Raised by Year of Establishment
  • 5.1.13. Concluding Remarks

6. GRANTS ANALYSIS

• 6.1. Scope and Methodology
• 6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health
  • 6.2.1. Analysis of Instances by Year
  • 6.2.2. Analysis of Amount Awarded by Year
  • 6.2.3. Popular Recipient Organizations: Analysis by Grant Amount
  • 6.2.4. Prominent Program Officers: Analysis by Number of Grants
  • 6.2.5. Analysis by Type of Recipient Organization
  • 6.2.6. Analysis of Instances by Year
  • 6.2.7. Analysis by Purpose of Grant Award
  • 6.2.8. Analysis by Funding Institute
  • 6.2.9. Analysis by Support Period
  • 6.2.10. Analysis by Funding Institute and Support Period
  • 6.2.11. Analysis by Activity Code
  • 6.2.12. Analysis by Type of Application
  • 6.2.13. Word Cloud of NIH Spending Categories

7. COMPANY COMPETITIVENESS

• 7.1. Key Assumptions and Parameters
• 7.2. Methodology
• 7.3. Benchmarking of Portfolio Strength
• 7.4. Benchmarking of Partnership Activity
• 7.5. Benchmarking of Funding Activity
• 7.6. Benchmarking of Portfolio Strength
• 7.7. NAMPT Inhibitors: Company Competitiveness Analysis

8. COMPANY PROFILES

• 8.1. Antengene Therapeutics
  • 8.1.1. Company Overview
  • 8.1.2. Funding Information
  • 8.1.3. Product Portfolio
  • 8.1.4. Recent Developments and Future Outlook
• 8.2. Aqualung Therapeutics
  • 8.2.1. Company Overview
  • 8.2.2. Funding Information
  • 8.2.3. Product Portfolio
  • 8.2.4. Patent Portfolio
  • 8.2.5. Recent Developments and Future Outlook
• 8.3. Karyopharm Therapeutics
  • 8.3.1. Company Overview
  • 8.3.2. Financial Information
  • 8.3.3. Product Portfolio
  • 8.3.4. Patent Portfolio
  • 8.3.5. Recent Developments and Future Outlook
• 8.4. OncoTartis
  • 8.4.1. Company Overview
  • 8.4.2. Funding Information
  • 8.4.3. Product Portfolio
  • 8.4.4. Patent Portfolio
  • 8.4.5. Recent Developments and Future Outlook
• 8.5. Onxeo
  • 8.5.1. Company Overview
  • 8.5.2. Financial Information
  • 8.5.3. Product Portfolio
  • 8.5.4. Recent Developments and Future Outlook

9. PUBLICATION ANALYSIS

• 9.1. Methodology and Key Parameters
• 9.2. NAMPT Inhibitors: List of Publications
  • 9.2.1. Analysis by Year of Publication
  • 9.2.2. Analysis by Type of Publication
  • 9.2.3. Most Popular Journals: Analysis by Number of Publications
  • 9.2.4. Most Popular Publishers: Analysis by Number of Publications
  • 9.2.5. Analysis by Journal Impact Factor
  • 9.2.6. Most Popular Journals: Analysis by Journal Impact Factor
  • 9.2.7. Analysis by Geography
  • 9.2.8. Emerging Focus Areas

10. GLOBAL EVENTS ANALYSIS

• 10.1. Methodology and Key Parameters
• 10.2. NAMPT Inhibitors: List of Global Events
  • 10.2.2. Cumulative Year-wise Trend
  • 10.2.3. Analysis by Type of Event
  • 10.2.4. Analysis by Event Platform
  • 10.2.5. Leading Players: Analysis by Number of Participants
  • 10.2.6. Leading Presenters: Analysis by Number of Participants
  • 10.2.7. Analysis by Geography

11 SOCIAL MEDIA ANALYSIS

• 11.1. Methodology and Key Parameters
  • 11.1.1. Cumulative Year-wise Activity
  • 11.1.2. Leading Users: Analysis by Number of Tweets
  • 11.1.3. Trending Words / Phrases on Twitter

12 DRUG FAILURE ANALYSIS

• 12.1. Methodology and Key Parameters
• 12.2. NAMPT Inhibitors: List of Failed Drug Candidates
  • 12.2.1. Analysis by Phase of Discontinuation
  • 12.2.2. Analysis by Trial Status
  • 12.2.3. Analysis by Target Indication
  • 12.2.4. Analysis by Route of Administration
  • 12.2.5. Analysis by Type of Sponsor
  • 12.2.6. Affiliated Stakeholders: Analysis by Number of Trials
  • 12.2.7. Analysis by Reasons for Drug Failure
  • 12.2.8. Key Terms in Study Results
  • 12.2.9. Other Plausible Reasons for Drug Failure

13 FDA APPROVAL STRATEGIES

• 13.1. Methodology and Key Parameters
• 13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers
• 13.3. Drug Specific Business Models followed by Company
• 13.4. Analysis of Drug Candidates by Business Model

14 MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 14.1. Key Assumptions and Parameters
• 14.2. Forecast Methodology
• 14.3. Global NAMPT Inhibitors Market, 2027-2040
• 14.4. List of Forecasted Drugs
  • 14.4.1. OT-82, OncoTartis
    • 14.4.1.1. Global Sales Forecast
    • 14.4.1.2. Regional Sales Forecast
    • 14.4.1.3. Net Present Value
    • 14.4.1.4. Value Creation Analysis
  • 14.4.2. ALT-100, Aqualung Therapeutics
    • 14.4.2.1. Global Sales Forecast
    • 14.4.2.2. Regional Sales Forecast
    • 14.4.2.3. Net Present Value
    • 14.4.2.4. Value Creation Analysis
  • 14.4.3. ATG-019, Antengene Therapeutics
    • 14.4.3.1. Global Sales Forecast
    • 14.4.3.2. Regional Sales Forecast
    • 14.4.3.3. Net Present Value
    • 14.4.3.4. Value Creation Analysis
  • 14.4.4. KPT-9274, Karyopharm Therapeutics
    • 14.4.4.1. Global Sales Forecast
    • 14.4.4.2. Regional Sales Forecast
    • 14.4.4.3. Net Present Value
    • 14.4.4.4. Value Creation Analysis
• 14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 2040
  • 14.5.1. NAMPT Inhibitors Market for Small Molecules, 2027-2040
  • 14.5.2. NAMPT Inhibitors Market for Biologics, 2029-2040
• 14.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 2040
  • 14.6.1. NAMPT Inhibitors Market for Oncological Disorders, 2027-2040
  • 14.6.2. NAMPT Inhibitors Market for Respiratory Disorders, 2029-2040
• 14.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 2040
  • 14.7.1. NAMPT Inhibitors Market for Non-Hodgkin Lymphoma, 2027-2040
  • 14.7.2. NAMPT Inhibitors Market for Hodgkin Lymphoma, 2027-2040
  • 14.7.3. NAMPT Inhibitors Market for Acute Respiratory Distress Syndrome, 2029-2040
  • 14.7.4. NAMPT Inhibitors Market for Acute Myeloid Leukemia, 2033-2040
• 14.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 2040
  • 14.8.1. NAMPT Inhibitors Market for First Line Therapies, 2027-2040
  • 14.8.2. NAMPT Inhibitors Market for Second Line Therapies, 2033-2040
• 14.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 2040
  • 14.9.1. NAMPT Inhibitors Market for Oral Therapies, 2027-2040
  • 14.9.2. NAMPT Inhibitors Market for Intravenous Therapies, 2029-2040
• 14.10. NAMPT Inhibitors: Market Share of Key Players
• 14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040

15 EXECUTIVE INSIGHTS

16 APPENDIX 1: LIST OF FIGURES

17 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

• Table 3.1 List of Drug Candidates
• Table 3.2 List of Drug Developers
• Table 4.1 NAMPT Inhibitors: Partnerships and Collaborations
• Table 5.1 NAMPT Inhibitors: Funding and Investment
• Table 6.1 List of Grants
• Table 8.1 Antengene: Funding Information (USD Million)
• Table 8.2 Antengene: Product Portfolio
• Table 8.3 Antengene: Recent Developments
• Table 8.4 Aqualung Therapeutics: Funding Information (USD Million)
• Table 8.5 Aqualung Therapeutics: Product Portfolio
• Table 8.6 Aqualung Therapeutics: Patent Portfolio
• Table 8.7 Aqualung Therapeutics: Recent Developments
• Table 8.8 Karyopharm Therapeutics: Financial Information (USD Million)
• Table 8.9 Karyopharm Therapeutics: Product Portfolio
• Table 8.10 Karyopharm Therapeutics: Patent Portfolio
• Table 8.11 Karyopharm Therapeutics: Recent Developments
• Table 8.12 OncoTartis: Funding Information (USD Million)
• Table 8.13 OncoTartis: Product Portfolio
• Table 8.14 OncoTartis: Patent Portfolio
• Table 8.15 Onxeo: Financial Information (EUR Million)
• Table 8.16 Onxeo: Product Portfolio
• Table 8.17 Onxeo: Recent Developments
• Table 9.1 NAMPT Inhibitors: List of Publications
• Table 10.1 NAMPT Inhibitors: List of Global Events
• Table 12.1 NAMPT Inhibitors: List of Failed Drug Candidates
• Table 14.1 OT-82: Net Present Value, 2027-2040
• Table 14.2 OT-82: Value Creation Analysis, 2027-2040
• Table 14.3 ALT-100: Net Present Value, 2029-2040
• Table 14.4 ALT-100: Value Creation Analysis, 2029-2040
• Table 14.5 ATG-019: Net Present Value, 2030-2040
• Table 14.6 ATG-019: Value Creation Analysis, 2030-2040
• Table 14.7 KPT-9274: Net Present Value, 2033-2040
• Table 14.8 KPT-9274: Value Creation Analysis, 2033-2040

LIST OF FIGURES

• Figure 3.1 Distribution by Phase of Development
• Figure 3.2 Distribution by Type of Molecule
• Figure 3.3 Distribution by Phase of Development and Type of Molecule
• Figure 3.4 Distribution by Type of Therapy
• Figure 3.5 Distribution by Line of Treatment
• Figure 3.6 Distribution by Route of Administration
• Figure 3.7 Distribution by Type of Player
• Figure 3.8 Distribution by Year of Establishment
• Figure 3.9 Distribution by Company Size
• Figure 3.10 Players in North America
• Figure 3.11 Players in Europe
• Figure 3.12 Players in Rest of the World
• Figure 3.13 Distribution by Stage of Development and Location of Headquarters
• Figure 3.14 Distribution by Type of Molecule and Location of Headquarters
• Figure 3.15 Distribution by Phase of Development and Location of Headquarters
• Figure 4.1 Distribution by Year of Partnership
• Figure 4.2 Distribution by Type of Partnership
• Figure 4.3 Distribution by Year and Type of Partnership
• Figure 4.4 Distribution by Type of Agreement
• Figure 4.5 Distribution by Intercontinental and Intracontinental Deals
• Figure 4.6 Distribution by Number of Partnerships
• Figure 5.1 Distribution by Annual Instances
• Figure 5.2 Distribution of Amount Invested by Year
• Figure 5.3 Year-wise Distribution of Instances by Type of Funding
• Figure 5.4 Year-wise Distribution of Amount Received and Type of Funding
• Figure 5.5 Distribution of Instances by Type of Funding
• Figure 5.6 Distribution of Amount Raised by Type of Funding
• Figure 5.7 Most Active Investors by Number of Instances
• Figure 5.8. Distribution by Number of Instances
• Figure 5.9 Distribution by Amount Received
• Figure 5.10 Distribution of Amount Raised by Geography
• Figure 5.11 Distribution of Amount Raised by Year of Establishment
• Figure 5.12 Concluding Remarks
• Figure 6.1 Distribution of Grants by Year
• Figure 6.2 Distribution of Amount Awarded by Year
• Figure 6.3 Key Organizations by Amount Received
• Figure 6.4 Distribution by Program Officers
• Figure 6.5 Type of Recipient Organization
• Figure 6.6 Distribution of Grants by Purpose of Award
• Figure 6.7 Distribution by Funding Institute
• Figure 6.8 Distribution by Support Period
• Figure 6.9 Distribution by Funding Institute and Support Period
• Figure 6.10 Distribution by Grant Activity Code
• Figure 6.11 Distribution by Type of Application
• Figure 6.12 Word Cloud of NIH Spending Categories
• Figure 7.1 Benchmarking by Prominent Players
• Figure 7.2 Distribution of Developers
• Figure 9.1 Distribution of Year of Publication
• Figure 9.2 Distribution of Type of Publication
• Figure 9.3 Most Popular Journals
• Figure 9.4 Most Popular Publisher
• Figure 9.5 Distribution by Journal Impact Factor
• Figure 9.6 Key Journals by Impact Factor
• Figure 9.7 Geographical Distribution of Affiliated Organizations
• Figure 9.8 Emerging Focus Areas
• Figure 10.1 Cumulative Year-wise Trend of Global Events
• Figure 10.2 Distribution by Type of Event
• Figure 10.3 Distribution by Type of Platform
• Figure 10.4 Leading Players by Number of Participations
• Figure 10.5 Leading Presenters by Number of Participations
• Figure 10.6 Geographical Distribution of Events
• Figure 11.1 Cumulative Year-wise Trend of Tweets
• Figure 11.2 Leading Users by Number of Tweets
• Figure 11.3 Trending Words / Phrases on Twitter
• Figure 12.1 Distribution by Phase of Discontinuation
• Figure 12.2 Distribution by Trial Status
• Figure 12.3 Distribution by Target Indication
• Figure 12.4 Distribution by Route of Administration
• Figure 12.5 Distribution by Type of Sponsor
• Figure 12.6 Distribution by Affiliated Stakeholders
• Figure 12.7 Distribution by Reason for Drug Failure
• Figure 12.8 Key Terms in Study Results
• Figure 12.9 Other Plausible Reasons for Drug Failure
• Figure 14.1 Global NAMPT Inhibitors Market, 2027-2040
• Figure 14.2 OT-82: Global Sales Forecast, 2027-2040
• Figure 14.3 OT-82: Regional Sales Forecast, 2027-2040
• Figure 14.4 ALT-100: Global Sales Forecast, 2029-2040
• Figure 14.5 ALT-100: Regional Sales Forecast, 2029-2040
• Figure 14.6 ATG-019: Global Sales Forecast, 2030-2040
• Figure 14.7 ATG-019: Regional Sales Forecast, 2030-2040
• Figure 14.8 KPT-9274: Global Sales Forecast, 2033-2040
• Figure 14.9 KPT-9274: Regional Sales Forecast, 2033-2040
• Figure 14.10 Distribution by Type of Molecule, 2027-2040
• Figure 14.11 Small Molecules: Regional Sales Forecast, 2027-2040
• Figure 14.12 Biologics: Regional Sales Forecast, 2029-2040
• Figure 14.13 Distribution by Therapeutic Area, 2027-2040
• Figure 14.14 Oncological Disorders: Regional Sales Forecast, 2027-2040
• Figure 14.15 Respiratory Disorders: Regional Sales Forecast, 2029-2040
• Figure 14.16 Distribution by Therapeutic Area, 2027-2040
• Figure 14.17 NHL: Regional Sales Forecast, 2027-2035
• Figure 14.18 Hodgkin Lymphoma: Regional Sales Forecast, 2027-2040
• Figure 14.19 ARDS: Regional Sales Forecast, 2029-2040
• Figure 14.20 AML: Regional Sales Forecast, 2033-2040
• Figure 14.21 Distribution by Line of Treatment, 2027-2040
• Figure 14.22 1st Line Therapies: Regional Sales Forecast, 2027-2040
• Figure 14.23 2nd Line Therapies: Regional Sales Forecast, 2033-2040
• Figure 14.24 Distribution by Route of Administration, 2027-2040
• Figure 14.25 Oral Therapies: Regional Sales Forecast, 2027-20401
• Figure 14.26 Intravenous Therapies: Regional Sales Forecast, 2029-2040
• Figure 14.27 Market Share of Key Players
• Figure 14.28 Distribution by Geography, 2030 and 2040